Cargando…

Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2

Increasing evidence suggests that the significance of the tumour immune microenvironment (TIME) for disease prognostication in invasive breast carcinoma is subtype-specific but equivalent studies in ductal carcinoma in situ (DCIS) are limited. The purpose of this paper is to review the existing data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Solek, Julia, Chrzanowski, Jedrzej, Cieslak, Adrianna, Zielinska, Aleksandra, Piasecka, Dominika, Braun, Marcin, Sadej, Rafal, Romanska, Hanna M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138378/ https://www.ncbi.nlm.nih.gov/pubmed/35625798 http://dx.doi.org/10.3390/biomedicines10051061

Ejemplares similares

Upregulation of HIF1-α via an NF-κB/COX2 pathway confers proliferative dominance of HER2-negative ductal carcinoma in situ cells in response to inflammatory stimuli
por: Piasecka, Dominika, et al.
Publicado: (2020)

MicroRNAs in regulation of triple-negative breast cancer progression
por: Piasecka, Dominika, et al.
Publicado: (2018)

A ‘Real-Life’ Experience on Automated Digital Image Analysis of FGFR2 Immunohistochemistry in Breast Cancer
por: Braun, Marcin, et al.
Publicado: (2020)

FGFs/FGFRs-dependent signalling in regulation of steroid hormone receptors – implications for therapy of luminal breast cancer
por: Piasecka, Dominika, et al.
Publicado: (2019)

Hormonal Receptor Status Determines Prognostic Significance of FGFR2 in Invasive Breast Carcinoma
por: Braun, Marcin, et al.
Publicado: (2020)

The diagnostic challenge in pulmonary tumour embolism in cancer: a case report and literature review
por: Zielińska, Aleksandra, et al.
Publicado: (2021)

Profiling of Invasive Breast Carcinoma Circulating Tumour Cells—Are We Ready for the ‘Liquid’ Revolution?
por: Braun, Marcin, et al.
Publicado: (2019)

FGF7/FGFR2–JunB signalling counteracts the effect of progesterone in luminal breast cancer
por: Mieczkowski, Kamil, et al.
Publicado: (2022)

FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ERα-Positive Breast Cancer Cells
por: Turczyk, Lukasz, et al.
Publicado: (2017)

Effect of Nutritional Habits on the Glycemic Response to Different Carbohydrate Diet in Children with Type 1 Diabetes Mellitus
por: Lejk, Agnieszka, et al.
Publicado: (2021)

Reduced Carbohydrate Diet Influence on Postprandial Glycemia—Results of a Short, CGM-Based, Interventional Study in Adolescents with Type 1 Diabetes
por: Lejk, Agnieszka, et al.
Publicado: (2022)

Fibroblast growth factor signalling induces loss of progesterone receptor in breast cancer cells
por: Piasecka, Dominika, et al.
Publicado: (2016)

Assessing Public Interest Based on Wikipedia’s Most Visited Medical Articles During the SARS-CoV-2 Outbreak: Search Trends Analysis
por: Chrzanowski, Jędrzej, et al.
Publicado: (2021)

Correction: Assessing Public Interest Based on Wikipedia’s Most Visited Medical Articles During the SARS-CoV-2 Outbreak: Search Trends Analysis
por: Chrzanowski, Jędrzej, et al.
Publicado: (2021)

Adenoid cystic carcinoma of the breast – an uncommon malignancy with unpredictable clinical behaviour. A case series of three patients
por: Sołek, Julia M., et al.
Publicado: (2021)

Neural Component of the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma
por: Gola, Michał, et al.
Publicado: (2022)

Lack of CD151/integrin α3β1 complex is predictive of poor outcome in node-negative lobular breast carcinoma: opposing roles of CD151 in invasive lobular and ductal breast cancers
por: Romanska, Hanna M, et al.
Publicado: (2015)

Interactions between FGFR2 and RSK2—implications for breast cancer prognosis
por: Czaplinska, Dominika, et al.
Publicado: (2016)

Ductal Carcinoma In Situ of the Breast: Perspectives on Tumor Subtype and Treatment
por: Liu, Yufei, et al.
Publicado: (2020)

The prognostic significance of immune microenvironment in breast ductal carcinoma in situ
por: Toss, Michael S., et al.
Publicado: (2020)

Liver metastasis or a pseudocyst? A rare presentation of leiomyosarcoma’s metastasis in the liver
por: Bednarek, Adrian, et al.
Publicado: (2022)

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
por: Estévez, Laura G, et al.
Publicado: (2014)

Insights into the transition of ductal carcinoma in situ to invasive ductal carcinoma: morphology, molecular portraits, and the tumor microenvironment
por: Chen, Weiling, et al.
Publicado: (2022)

An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ
por: Behbod, Fariba, et al.
Publicado: (2009)

Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast
por: Kim, Milim, et al.
Publicado: (2020)

Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells
por: Agahozo, Marie Colombe, et al.
Publicado: (2021)

Biphasic composite of calcium phosphate-based mesoporous silica as a novel bone drug delivery system
por: Prokopowicz, Magdalena, et al.
Publicado: (2019)

Mesoporous Silica-Bioglass Composite Pellets as Bone Drug Delivery System with Mineralization Potential
por: Szewczyk, Adrian, et al.
Publicado: (2021)

Hormone Receptor Subtype in Ductal Carcinoma in Situ: Prognostic and Predictive Roles of the Progesterone Receptor
por: Hwang, Ki‐Tae, et al.
Publicado: (2021)

Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy
por: Yang, Libo, et al.
Publicado: (2022)

Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ
por: Sameni, Mansoureh, et al.
Publicado: (2017)

Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection
por: Glencer, Alexa C., et al.
Publicado: (2021)

Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes
por: Watson, Spencer S., et al.
Publicado: (2018)

HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ
por: Rakovitch, E, et al.
Publicado: (2012)

Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling
por: Pradeep, Chaluvally-Raghavan, et al.
Publicado: (2011)

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
por: Groen, Emma J., et al.
Publicado: (2021)

Vav2 protein overexpression marks and may predict the aggressive subtype of ductal carcinoma in situ
por: Jiang, YunQing, et al.
Publicado: (2014)

Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact
por: Schandiz, Hossein, et al.
Publicado: (2023)

The role of stromal immune microenvironment in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer
por: Niwińska, Anna, et al.
Publicado: (2021)

CD8(+) tumor‐infiltrating lymphocytes contribute to spontaneous “healing” in HER2‐positive ductal carcinoma in situ
por: Morita, Michi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_27d0l0n9ofvqpacpaeq6nm67bb